Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases

Figure 5 Comparison of various conditioning regimens in Hodgkin lymphoma. A: Comparison of progression free survival (PFS) and overall survival (OS) between carmustine, etoposide, cytarabine, and melphalan (BEAM) [carmustine 300 mg/m² given at day 6, etoposide 200 mg/m² and cytarabine 200 mg/m² between day 2 to day 5, melphalan (MEL) 140 mg/m² at day 1] and mitoxantrone (MITO) 60 mg/m² in three divided doses at day 5 along with MEL 180 mg/m² in three divided doses at day 2 constituting a group with MITO/MEL; B: Comparison of PFS and OS between BEAM (n = 313), CBV-low (cyclophosphamide, carmustine, and etoposide) (n = 279), and CBV-high (cyclophosphamide, carmustine, and etoposide) (n = 219). PFS: Progression free survival; OS: Over survival; BEAM: Carmustine, etoposide, cytarabine, and melphalan; MITO: Mitoxantrone; MEL: Melphalan.